Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Post-CDK4/6 inhibitor therapy in HR+/HER2– advanced breast cancer: expanding options and persisting uncertainties

Endocrine treatment in combination with CDK4/6 inhibitors represents the mainstay of first-line palliative treatment in HR+/HER2– breast cancer. The treatment landscape after progression on CDK4/6 inhibitors has evolved into a complex and rapidly evolving field, driven by novel endocrine and targeted agents, new combin...

Anne-Murielle Hollinger, R. Bill · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.